Form 4: Allogene Director Joshua Kazam Acquires Shares

Allogene Therapeutics Director Joshua Kazam acquired 47,700 shares of common stock through the vesting of restricted stock units, correcting a prior reporting error.

Summary

• Joshua A. Kazam, a Director of Allogene Therapeutics, Inc. (ALLO), acquired 47,700 shares of common stock.
• The acquisition occurred on December 18, 2025, through the vesting of Restricted Stock Units (RSUs).
• The transaction price for the acquired shares was $0, which is typical for RSU conversions.
• Following this transaction, Kazam beneficially owns 350,763 shares of common stock directly.
• An earlier grant on June 23, 2025, was erroneously reported as 94,500 shares and is now corrected with this vesting.
• Each RSU represents a contingent right to receive one share of the company's common stock or cash in lieu thereof, at the Issuer's discretion.
• The RSUs are structured to vest in two successive equal semi-annual installments over a one-year period from the grant date, subject to continued service.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (RSU vesting) which increases a director's direct ownership, generally seen as a neutral to slightly positive signal. The correction of a prior reporting error also adds to transparency.

Positives

• Director Joshua A. Kazam increased his direct beneficial ownership of Allogene Therapeutics common stock by 47,700 shares, which can signal continued alignment with shareholder interests.
• The company corrected a previously misreported grant amount from June 23, 2025, demonstrating transparency in its reporting practices.

Negatives

• A previous RSU grant on June 23, 2025, was erroneously reported as 94,500 shares, requiring a correction in this filing.

Future Outlook

The remaining Restricted Stock Units (RSUs) are scheduled to vest in one additional equal semi-annual installment over the one-year period from the grant date, contingent on continued service.

Related Party Transactions

• The vesting of Restricted Stock Units (RSUs) for Director Joshua A. Kazam represents a compensation-related transaction with a related party.

Stakeholder Impact

• Shareholders: The increase in director ownership, even through routine vesting, may be viewed as a minor positive signal of management's continued alignment with the company's performance.

Next Steps

• The remaining portion of the Restricted Stock Units (RSUs) will vest in one more equal semi-annual installment, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units (RSUs) for a director. While it increases the director's beneficial ownership, it does not represent an open market purchase or sale that would significantly alter the investment thesis for Allogene Therapeutics. Therefore, it does not provide new information warranting a change from a 'hold' recommendation based solely on this filing.

Keywords

Allogene Therapeutics, ALLO, Form 4, insider transaction, stock acquisition, RSU vesting, director ownership, Joshua Kazam